Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Nurix Therapeutics's operating margin for the twelve months ending Aug 31, 2026 was 41.3%. For fiscal 2025 it was -340.2%, against -390.5% the year before. The highest annual figure on record is -71.5% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | -340.2% | +50.4 |
| FY2024 | Nov 30, 2024 | -390.5% | −189.1 |
| FY2023 | Nov 30, 2023 | -201.4% | +274.6 |
| FY2022 | Nov 30, 2022 | -476.0% | −79.8 |
| FY2021 | Nov 30, 2021 | -396.3% | −31.6 |
| FY2020 | Nov 30, 2020 | -364.7% | −293.2 |
| FY2019 | Nov 30, 2019 | -71.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | 83.1% | +1240.8 |
| Q2 FY2026CQ2 2026 | May 31, 2026 | -1041.7% | −932.1 |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | -1479.4% | −1138.8 |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | -612.0% | −125.3 |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | -1157.7% | −723.8 |
| Q2 FY2025CQ2 2025 | May 31, 2025 | -109.7% | +291.7 |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | -340.7% | −68.0 |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | -486.7% | −187.7 |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | -433.8% | −217.2 |
| Q2 FY2024CQ2 2024 | May 31, 2024 | -401.4% | −314.2 |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | -272.6% | +66.0 |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | -299.1% | +418.8 |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | -216.7% | +216.3 |
| Q2 FY2023CQ2 2023 | May 31, 2023 | -87.3% | +312.6 |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | -338.6% | +105.7 |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | -717.8% | −204.7 |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | -432.9% | −150.1 |
| Q2 FY2022CQ2 2022 | May 31, 2022 | -399.9% | −27.4 |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | -444.3% | +45.1 |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | -513.2% | −214.0 |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | -282.8% | +187.0 |
| Q2 FY2021CQ2 2021 | May 31, 2021 | -372.5% | −56.1 |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | -489.4% | −51.1 |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | -299.1% | +429.3 |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | -469.8% | −445.1 |
| Q2 FY2020CQ2 2020 | May 31, 2020 | -316.4% | – |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | -438.3% | – |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | -728.5% | – |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | -24.7% | – |
See a number that looks wrong?